Zealand Announces Collaboration with Eli Lilly - - BioPharm International

ADVERTISEMENT

Zealand Announces Collaboration with Eli Lilly



Zealand Pharma, a biopharmaceutical company based in Copenhagen specializing in peptides, has formed a peptide drug R+D collaboration agreement with Eli Lilly.

Under the agreement, Zealand will collaborate with Eli Lilly in the design and development of peptide therapeutics for the treatment of Type 2 diabetes and obesity. The companies will share in the funding, risk, and reward of the program. Future expansion of the collaboration to additional drug targets and disease areas is possible. No financial terms of the agreement have been disclosed.

Source: Zealand Pharma

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Personalized Cell Therapy Receives FDA Breakthrough Therapy Designation
July 9, 2014
FDA Urged to Preserve Biosimilar Naming Conventions
July 2, 2014
Merck Collaborates with Bionomics on Alzheimer's Treatments
July 1, 2014
EMA Revises Guidance on Advanced Therapies
July 1, 2014
EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates
July 1, 2014
Author Guidelines

Click here